Overview
Biopharmaceutical firm's Q4 net loss widened due to increased R&D expenses
Company reported strong year-end cash position to support pipeline execution
Result Drivers
STRATEGIC COLLABORATION - Collaboration with Bristol Myers Squibb provides capital and validates Janux's platform, with potential for milestone payments and royalties
CASH POSITION - Strong year-end cash position supports continued pipeline execution
Company press release: ID:nBw3cHvrVa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income | -$42.40 mln | ||
Q4 Basic EPS | -$0.51 | ||
Q4 Operating Expenses | $42.40 mln | ||
Q4 Operating Income | -$42.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Janux Therapeutics Inc is $53.50, about 290.5% above its February 25 closing price of $13.70
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)